Angelica injection promotes peripheral nerve structure and function recovery with increased expressions of nerve growth factor and brain derived neurotrophic factor in diabetic rats

Current Neurovascular Research

Volumn 7, Issue 3, 2010, Pages 213-222

  Li, Ruilin ^a   Zhang, Junjian ^a   Zhang, Lei ^a   Cui, Qin ^a   Liu, Hui ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Angelica injection; Brain derived neurotrophic factor; Diabetic peripheral neuropathy; Nerve growth factor; Sciatic nerve

Indexed keywords

ANGELICA EXTRACT; BRAIN DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; STREPTOZOCIN;

ANGELICA; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG INDUCED DISEASE; DRUG MEGADOSE; INJECTION; LOW DRUG DOSE; MALE; MORPHOLOGY; MOTOR NERVE CONDUCTION; MYELINATED NERVE; NONHUMAN; PERIPHERAL NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCIATIC NERVE; SOLEUS MUSCLE; TAIL FLICK TEST; TREATMENT DURATION; WESTERN BLOTTING;

EID: 77956520609     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720210792231796     Document Type: Article

References (39)

1. Pourmand R. Diabetic neuropathy. Neurol Clin 1997; 15(3): 569-76.
2. Sugimoto K, Murakawa Y, Sima AA.F. Diabetic neuropathy-a continuing enigma. Diabetes Metab Res Rev 2000; 16(6): 408-33.
3. Anders A.F. Acetyl-L-Carnitine in diabetic polyneuropathy experimental and clinical data. CNS Drugs 2007; 21(1): 13-23.
4. Stuart C, Apfel, S.C. Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol 1999; 41(Suppl 1): 27-34.
5. Kim HC, Cho YJ, Ahn CW, et al. Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabet Med 2009; 26(12): 1228-34.
6. Andreassen CS, Jakobsen J, Flyvbjerg A, Andersen H. Expression of neurotrophic factors in diabetic muscle-relation to neuropathy and muscle strength. Brain 2009; 132: 2724-33
7. Sinicropi DV, McCaffrey DS, Williams PM, et al. Decreased skin mRNAs for NGF, BDNF, NT-3, GDNF but not NT4/5 or trkA/p75 in sub-clinical human diabetic neuropathy. Proc XVII World Congr Neurol 2001; pp. 18-22.
8. Pittenger G, Vinik A. Nerve growth factor and diabetic neuropathy. Exp Diabes Res 2003; 4(4): 271-85.
9. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Rask C.A. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998; 51(3): 695-702.
10. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Escandon E. Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. J Neuropathol Exp Neurol 2001; 60(3): 263-73.
11. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. rhNGF Clinical investigator group. JAMA 2000; 284(17): 2215-21.
12. Wellmer A, Misra VP, Sharief MK, Kopelman PG, Anand P. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst 2001; 6(4): 204-10.
13. Kakinoki B, Sekimoto S, Yuki S, et al. Orally active neurotrophinenhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. Diabetes 2006; 55(3): 616-21.
14. Nitta A, Ito M, Fukumitsu H, et al. 4-Methylcatechol increases brain-derived neurotrophic factor content and mRNA expression in cultured brain cells and in rat brain in vitro. J Pharmacol Exp Ther 1999; 291(3): 1276-83.
15. Calcutt NA, Freshwater JD, Hauptmann N, Taylor EM, Mizisin AP. Protection of sensory function in diabetic rats by Neotrofin. Eur J Pharmacol 2006; 534(1-3): 187-93.
16. Zheng P, Zhang JJ, Liu H, Xu X, Zhang X. Angelica injection reduces cognitive impairment during chronic cerebral hypoperfusion through brain-derived neurotrophic factor and nerve growth factor. Curr Neurovasc Res 2008; 5(1): 13-20.
17. Cui Q, Zhang JJ, Zhang L, Li RL, Liu H. Angelica injection improves functional recovery and motoneuron maintenance with increased expression of brain derived neurotrophic factor and nerve growth factor. Curr Neurovasc Res 2009; 6(2): 117-23.
18. Perkins BA, Bril V. Diabetic neuropathy: A review emphasizing diagnostic methods. Clin Neurophysiol 2003; 114(7): 1167-75.
19. Calcutt, N.A. Modeling diabetic sensory neuropathy in rats. Methods Mol Med 2004; 99: 55-65.
20. Arezzo JC, Zotova E. Electrophysiologic measures of diabetic neuropathy: Mechanism and meaning. Int Rev Neurobiol 2002; 50: 229-55.
21. Kumar S, Arun KHS, Kaul CL, Sharma S.S. Effects of adenosine and adenosine A2A receptor agonist on motor nerve conduction velocity and nerve blood flow in experimental diabetic neuropathy. Neurol Res 2005; 27(1): 60-6.
22. Sufyan G, Ashutosh K, Shyam S. Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy. Life Sci 2006; 79(8): 777-83.
23. Wei SY, Zhang PX, Yang DM, Zhang HB, Jiang B.G. The medicine and lotrel of promoting peripheral nerve regeneration medicine and lotrel. China J Chinese Mat Med 2008; 33(17): 2069-72.
24. Chen HF, Xiao JS, Li X.N. Clinical observation of angelica injection in treating diabetic peripheral neuropathy. J Math Med 2006; 19(5): 495-6.
25. Comelli F, Bettoni I, Colombo A, et al. Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. Eur J Pharmacol 2010; 637(1-3): 62-9.
26. Tsuyoshi M, Nozomu S, Hiroyuki T, et al. synthesis and biological activity of novel 5-(w-aryloxyalkyl) oxazole derivatives as brainderived neurotrophic factor inducers Chem. Pharm Bull 2003; 51(5): 565-73.
27. Hernández-Pedro N, Ordónez G, Ortiz-Plata A, et al. Alltransretinoic acid induces nerve regeneration and increases serum and nerve contents of neural growth factor in experimental diabetic neuropathy. Transl Res 2008; 152(1): 31-7.
28. Sima AA.F. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003; 60(11): 2445-64.
29. Calcutt NA, Jolivalt CG, Fernyhough P. Growth factors as therapeutics for diabetic neuropathy. Curr Drug Targets. 2008; 9(1): 47-59.
30. Christianson JA, Ryals JA, Johnson MS, Dobrowsky RT, Wright D.E. Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice. Neuroscience 2007; 145(1): 303-13.
31. Fernyhough P, Diemel LT, Brewster WJ, Tomlinson D.R. Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats. J Neurochem 1995; 64(3): 1231-7.
32. de Carrizosa MA, Morado-Diaz CJ, Tena JJ, et al. Complementary actions of BDNF and neurotrophin-3 on the firing patterns and synaptic composition of motoneurons. J Neurosci 2009; 29(2): 575-87.
33. Cotter MA, Love A, Cameron N.E. Effects of neurotrophins on nerve function and regeneration in young diabetic rats. Diabetes 1997; 46(Suppl 1): 126.
34. Apfel SC, Wright DE, Wiideman AM, et al. Nerve growth factor regulates the expression of brain derived neurotrophic factor mRNA in the peripheral nervous system. Mol Cell Neurosci 1996; 7(2): 134-42.
35. Michael GJ, Averill S, Nitkunan A, Rattray M. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in trkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci 1997; 17(21): 8476-90.
36. Nakagawa T, Tsuchida A, Itakura Y, et al. Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. Diabetes 2000; 49(3): 436-44.
37. Yamanaka M, Itakura Y, Ono-Kishino M, et al. Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. J Biosci Bioeng 2008; 105(4): 395-402.
38. Xu L, Dong Z, Chen H, Yi D. Effect of ASP on study and memory senility caused by D-galactose in rats. Laser J 2008; 29(2): 92-3.
39. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(10): 813-20.